Uniqure NV (NASDAQ:QURE) — Market Cap & Net Worth
Market Cap & Net Worth: Uniqure NV (QURE)
Uniqure NV (NASDAQ:QURE) has a market capitalization of $1.46 Billion ($1.46 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7505 globally and #2197 in its home market, demonstrating a -0.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Uniqure NV's stock price $26.99 by its total outstanding shares 62291663 (62.29 Million). Review Uniqure NV balance sheet liabilities to assess the company's total debt and financial obligations.
Uniqure NV Market Cap History: 2015 to 2026
Uniqure NV's market capitalization history from 2015 to 2026. Data shows growth from $1.03 Billion to $1.68 Billion (3.42% CAGR).
Index Memberships
Uniqure NV is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.06% | #205 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #810 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.09% | #127 of 263 |
Weight: Uniqure NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Uniqure NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Uniqure NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
40.56x
Uniqure NV's market cap is 40.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.03 Billion | $10.30 Million | -$78.15 Million | 99.99x | N/A |
| 2016 | $348.83 Million | $25.10 Million | -$73.37 Million | 13.90x | N/A |
| 2017 | $1.22 Billion | $13.11 Million | -$80.39 Million | 93.10x | N/A |
| 2018 | $1.80 Billion | $11.28 Million | -$83.30 Million | 159.10x | N/A |
| 2019 | $4.46 Billion | $7.28 Million | -$124.20 Million | 613.08x | N/A |
| 2020 | $2.25 Billion | $37.51 Million | -$125.02 Million | 59.99x | N/A |
| 2021 | $1.29 Billion | $524.00 Million | $329.59 Million | 2.47x | 3.92x |
| 2022 | $1.41 Billion | $106.48 Million | -$126.79 Million | 13.26x | N/A |
| 2023 | $421.71 Million | $15.84 Million | -$308.48 Million | 26.62x | N/A |
| 2024 | $1.10 Billion | $27.12 Million | -$239.56 Million | 40.56x | N/A |
Competitor Companies of QURE by Market Capitalization
Companies near Uniqure NV in the global market cap rankings as of June 17, 2026.
Key companies related to Uniqure NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Uniqure NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Uniqure NV's market cap moved from $1.03 Billion to $ 1.68 Billion, with a yearly change of 3.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.68 Billion | +12.79% |
| 2025 | $1.49 Billion | +35.50% |
| 2024 | $1.10 Billion | +160.86% |
| 2023 | $421.71 Million | -70.14% |
| 2022 | $1.41 Billion | +9.31% |
| 2021 | $1.29 Billion | -42.60% |
| 2020 | $2.25 Billion | -49.58% |
| 2019 | $4.46 Billion | +148.65% |
| 2018 | $1.80 Billion | +47.12% |
| 2017 | $1.22 Billion | +249.82% |
| 2016 | $348.83 Million | -66.14% |
| 2015 | $1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Uniqure NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.46 Billion USD |
| MoneyControl | $1.46 Billion USD |
| MarketWatch | $1.46 Billion USD |
| marketcap.company | $1.46 Billion USD |
| Reuters | $1.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more